RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Aiming, No, for the maintenance of analgesia data to be useful, it has to be concurrent with at least reasonably good RD prevention. So there are two ways for us to wind up with useless analgesia data -

1) The procedural problems that occurred in RD-2 (anxiety, loose masks, etc), occurred again in RD-1.

or -

2) There were no procedural problems, but 1500 mg produced little/no RD efficacy.